For questions about the program for the 2023 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Deputy Director of Scientific Affairs Alice Kuaban at?akuaban@hematology.org. For general inquiries about this meeting, please submit them to?ashsummit@hematology.org....
In the field of thrombosis and hemostasis the focus was laid on the prophylaxis and treatment of venous thromboembolism in patients with active cancer during this years' meeting of the American Society of Hematology (ASH) in San Diego. The Adam-VTE trial completed the series of studies using ...
The2024 American Society of Hematology (ASH) Annual Meeting and Expositionwas held in San Diego on December 7-10. Several sessions focused onparoxysmal nocturnal hemoglobinuria (PNH), highlighting emerging treatment options such as oral monotherapy, and new research on managing the condition. Key sess...
Previous studies have revealed an important role of ASH1L in leukemogenesis mediated by MLL fusion proteins9, however, the requirement for the catalytic SET domain in this process was unknown. To address this question, we took advantage of a mouse model with an in-frame deletion of the Ash1l ...
“This, like enasidenib (Idhifa), is a drug that [researchers] were able to dose escalate from very low doses to very high doses,” explained Alexander Perl, MD, member of the Leukemia Program in the Abramson Cancer Center and an associate professor in the Division of Hematology/Oncology...
This review focuses on the different treatment options available for the treatment of Hodgkin's disease, with an emphasis on the importance of the long-term sequelae of these therapies. In Section I, Dr. Linch reviews the current status ... Linch,C D. - 《Hematology》 被引量: 169发表: ...
be noted that in the APASS study, aPL antibodies were only tested at the time of the stroke (in contrast to the Sydney criteria for APS diagnosis,13 139 Hematology 2007 which require confirmatory retesting after 12 weeks), thereby including patients who might not have this diagnosis by current...